<SEC-DOCUMENT>0000947871-17-000962.txt : 20171121
<SEC-HEADER>0000947871-17-000962.hdr.sgml : 20171121
<ACCEPTANCE-DATETIME>20171121060456
ACCESSION NUMBER:		0000947871-17-000962
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171120
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171121
DATE AS OF CHANGE:		20171121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12215
		FILM NUMBER:		171215335

	BUSINESS ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ss68542_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<title></title>
</head>
<body style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" bgcolor="#ffffff">
<!--PROfilePageNumberReset%Num%1%%%-->
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" size="4" noshade>
<hr style="MARGIN-TOP: -10px; COLOR: #000000" size="1" noshade>
</div>

<div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">WASHINGTON, DC 20549</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">&#160;&#160; </div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<hr style="WIDTH: 100%; COLOR: black" align="left" size="1" noshade>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;&#160; <br>
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">FORM&#160;8-K</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt"></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<hr style="TEXT-ALIGN: center; WIDTH: 100%; HEIGHT: 1px; COLOR: black; MARGIN-LEFT: auto; MARGIN-RIGHT: auto" align="center" noshade>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE SECURITIES EXCHANGE ACT OF 1934</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of Report</font> (Date of Earliest Event Reported)<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">: November 20, 2017</font></div>
</div>

<div>&#160;</div>

<div>
<hr style="TEXT-ALIGN: center; WIDTH: 100%; HEIGHT: 1px; COLOR: black; MARGIN-LEFT: auto; MARGIN-RIGHT: auto" align="center" noshade>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quest Diagnostics Incorporated</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">(Exact Name of Registrant as Specified in Its Charter)</div>

<div>&#160;</div>
</div>

<div>
<hr style="TEXT-ALIGN: center; WIDTH: 100%; HEIGHT: 1px; COLOR: black; MARGIN-LEFT: auto; MARGIN-RIGHT: auto" align="center" noshade>
</div>
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">Delaware</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">(State or other jurisdiction of Incorporation)</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;&#160; </div>

<div style="TEXT-ALIGN: center">
<table style="WIDTH: 100%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" id="ze03355c707f74736b8c9a2b40785d392" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%" valign="top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">001-12215</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">(Commission File Number)</div>
</td>
<td style="WIDTH: 50%" valign="top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">16-1387862</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">(I.R.S. Employer Identification No.)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" valign="top">&#160;</td>
<td style="WIDTH: 50%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" valign="top">&#160;</td>
<td style="WIDTH: 50%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">
<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">500 Plaza Drive</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Secaucus, NJ</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 50%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">07094</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 50%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">(Address of principal executive offices)</div>
</td>
<td style="WIDTH: 50%" valign="top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">(Zip Code)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 50%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%" valign="top" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">(973) 520-2700</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">(Registrant&#8217;s telephone number, including area code)</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<hr style="TEXT-ALIGN: center; WIDTH: 100%; HEIGHT: 1px; COLOR: black; MARGIN-LEFT: auto; MARGIN-RIGHT: auto" align="center" noshade>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 39.6pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">Emerging growth company<font style="FONT-FAMILY: Wingdings; FONT-SIZE: 10pt"> o</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160; <font style="FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" size="1" noshade>
<hr style="MARGIN-TOP: -13px; COLOR: #000000" size="4" noshade>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal" id="DSPFPageNumber">1</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 8.01 Other Events</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 39.6pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">On November 20, 2017, Quest Diagnostics Incorporated (the &#8220;Company&#8221;) issued a press release providing an update on the financial impact of the Centers for Medicare and Medicaid Services&#8217; publication of finalized Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule pursuant to the Protecting Access to Medicare Act (&#8220;PAMA&#8221;) announced November 17, 2017. The Company expects the impact of the final fee schedule rates under PAMA to be approximately 4% in 2018, and approximately 10% in both 2019 and 2020.&#160; The Company will host a conference call to discuss these matters on Tuesday, November 21, 2017 at 8:30 a.m. Eastern Time.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 39.6pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">A copy of the press release, dated November 20, 2017, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item&#160;9.01 Financial Statements and Exhibits</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(d)&#160; &#160; &#160; &#160; &#160;&#160; Exhibits</div>

<div><br>
</div>

<div>&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zbaf2dadcf5b844f6a79d52983d5494a0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9.3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 10.62%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Exhibit</u></div>
</td>
<td style="WIDTH: 80.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 12.6pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Description</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 10.62%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 80.08%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 9.3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 10.62%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="ss68542_ex9901.htm">99.1</a></div>
</td>
<td style="WIDTH: 80.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 12.6pt; FONT-SIZE: 10pt"><a href="ss68542_ex9901.htm">Press Release announcing the PAMA update, dated November 20, 2017</a></div>
</td>
</tr>
</table>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Signature</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 39.6pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 39.6pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<table style="WIDTH: 100%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" id="z6518df79c17046ce9452dc256b96af3b" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 40%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="top" colspan="3">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">November 21, 2017</div>
</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 40%" valign="top" colspan="3">&#160;</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 40%; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="top" colspan="3">QUEST DIAGNOSTICS INCORPORATED</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 4%" valign="top">&#160;</td>
<td style="WIDTH: 6%" valign="top">&#160;</td>
<td style="WIDTH: 30%" valign="top">&#160;</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 4%" valign="top">&#160;</td>
<td style="WIDTH: 6%" valign="top">&#160;</td>
<td style="WIDTH: 30%" valign="top">&#160;</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 50%" valign="top">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 4%" valign="top" nowrap>By: </td>
<td style="BORDER-BOTTOM: black 2px solid; WIDTH: 6%" valign="top" colspan="2" nowrap>&#160;/s/ William J. O&#8217;Shaughnessy, Jr.</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 4%" valign="top">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 6%" valign="top" colspan="2" nowrap>William J. O&#8217;Shaughnessy, Jr.</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 4%" valign="top">&#160;</td>
<td style="WIDTH: 6%" valign="top" colspan="2" nowrap>
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; FONT-SIZE: 10pt">Deputy General Counsel and Secretary</div>
</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 4%" valign="top">&#160;</td>
<td style="WIDTH: 6%" valign="top">&#160;</td>
<td style="WIDTH: 30%" valign="top">&#160;</td>
<td style="WIDTH: 10%" valign="top">&#160;</td>
</tr>
</table>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2&#160;</font>

<div>
<hr style="WIDTH: 100%; COLOR: black" align="left" size="2" noshade>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ss68542_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<title></title>
</head>
<body style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5%; FONT-SIZE: 10pt; MARGIN-RIGHT: 5%" bgcolor="#ffffff">
<div style="TEXT-ALIGN: right; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: right; FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 99.1</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quest Diagnostics Provides Update on Impact of Final 2018 Medicare Payment Rates for Clinical Laboratory Tests</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">SECAUCUS, N.J., Nov. 20, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world&#8217;s leading provider of diagnostic information services, today provided an update on the impact of the Centers for Medicare and Medicaid Services (CMS) publication of finalized 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule (CLFS) pursuant to the Protecting Access to Medicare Act (PAMA) announced&#160;November 17, 2017.</div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt"><img src="image01.jpg"></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0pt">
<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">&#8220;We are deeply disappointed that CMS did not take into account much of the feedback received from across the healthcare ecosystem,&#8221; said&#160;Steve Rusckowski, Chairman, President and CEO of Quest Diagnostics.&#160; &#8220;While we acknowledge adjustments to a few of the most egregious elements of the proposed fee schedule, the final fee schedule remains deeply flawed because it is plagued by a&#160;distorted market data collection process that excluded key components of the lab market. As an example, less than 1 percent of all laboratories submitted data, and over 99 percent of hospital and physician office laboratories were prohibited from reporting their rates.&#160; Also, based on the data submitted to CMS, Quest alone represented nearly 40 percent of all the market data CMS collected despite accounting for less than 15 percent of Medicare claims under CLFS.&#8221;&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">The company expects the impact of the final fee schedule rates under PAMA to be approximately 4% in 2018, and approximately 10% in both 2019 and 2020.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">Mr. Rusckowski continued, &#8220;These cuts will hurt the industry and our company. We have begun to plan for the worst case, and, as we have said previously, despite the flawed implementation of PAMA, we remain confident in our ability to meet the long-term financial commitments outlined at our 2016 Investor Day.&#8221;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">Conference Call Information</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">Quest Diagnostics will hold a conference call to discuss the financial impact of the final 2018 Medicare payment rates beginning at&#160;8:30 a.m. Eastern Time Tuesday, November 21, 2017.&#160; The conference call can be accessed in listen-only mode by dialing&#160;773-756-0467, passcode 3214469. The company suggests participants dial in approximately 10 minutes before the call.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">A replay of the call may be accessed online at&#160;</font><font style="FONT-FAMILY: Arial; COLOR: #0000ff; FONT-SIZE: 10pt"><u>www.QuestDiagnostics.com/investor</u></font><font style="FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">&#160;or by phone at 800-839-2313 for domestic callers or&#160;203-369-3137&#160;for international callers. Telephone replays will be available from approximately 10:30 a.m. Eastern Time&#160;on&#160;November 21, 2017&#160;until&#160;midnight Eastern Time&#160;on&#160;December 5, 2017.&#160; Anyone listening to the call is encouraged to read the company&#8217;s periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.</font></div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">About Quest Diagnostics&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world&#8217;s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in&#160;the&#160;United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.&#160;</font><font style="FONT-FAMILY: Arial; COLOR: #0000ff; FONT-SIZE: 10pt"><u>www.QuestDiagnostics.com</u></font><font style="FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">50th Anniversary: In 2017, Quest Diagnostics celebrates 50 years of life-changing results. To learn about our legacy of accomplishments and quest to improve healthcare in the future, visit&#160;</font><font style="FONT-FAMILY: Arial; COLOR: #0000ff; FONT-SIZE: 10pt"><u>www.QuestDiagnostics.com/50Years</u></font><font style="FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">.</font></div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Arial; COLOR: #000000; FONT-SIZE: 10pt">CONTACT: Dennis Moynihan, 973-520-2192, dennis.j.moynihan@questdiagnostics.com</div>

<div>&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
<div>
<hr style="WIDTH: 100%; COLOR: black" align="left" size="2" noshade>
</div>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$,17AI9@  34T *@    @ ! $[  (
M   6   (2H=I  0    !   (8)R=  $    L   0V.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9E;FEC92!,
M:6YD;RU4:&]M<'-O;@  !9 #  (    4   0KI $  (    4   0PI*1  (
M   #,34  )*2  (    #,34  .H<  <   @,   (H@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 #(P,3<Z,3$Z,C @,C$Z,# Z,S4
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M1VWDR'[[=XP?0=_7I7H/C/7#X=\)7VH(?WRILA'_ $T;A?U.?PKR?X:>%?\
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M=_,5QWV.>5;V->Q66MZ??:%%K$-R@L9(O-$SG:%7WSTQWK ^*-K!=?#?53<
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8HH *3%+10 F*,4M% !BBBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
